Nardilysin activators are chemical compounds designed to enhance the activity of nardilysin, a zinc-dependent metalloendopeptidase known by the scientific community as N-arginine dibasic convertase or NRD1. This protein plays a pivotal role in the intricate process of proteolysis, where it cleaves protein substrates at specific dibasic sites, thus participating in the regulation of various peptides and proteins that are essential for cellular functions.
The mechanism by which nardilysin activators function can be direct, such as by binding to the active site of nardilysin and promoting a conformational change that increases its enzymatic activity. This could entail stabilization of the enzyme's structure or altering its dynamics to favor the catalytic process. Alternatively, activators may work indirectly, possibly by upregulating the expression of nardilysin or by enhancing its maturation and trafficking to the appropriate cellular compartments where its substrates are located. The precise scientific exploration into the activation of nardilysin is driven by a fascination with understanding the protein's role in the cleavage and modification of key signaling molecules. By studying how nardilysin activators affect its function, researchers can uncover the subtle nuances of intracellular and extracellular communication mediated by peptide processing. Experimental methods in this domain often include biochemical assays to quantify enzymatic activity, studies of protein-protein interactions to observe the effects of activation on nardilysin's interaction partners, and cellular localization experiments to track the distribution of nardilysin within the cell upon activation.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin activates adenylate cyclase, an enzyme that catalyzes the conversion of ATP to cAMP. Increased cAMP levels activate protein kinase A (PKA), which modulates the transcription of nardilysin, leading to higher expression levels. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $77.00 $216.00 | 18 | |
Rolipram inhibits phosphodiesterase 4 (PDE4), an enzyme that breaks down cAMP. Increased cAMP levels, in turn, activate PKA, potentially enhancing nardilysin expression. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
IBMX is a non-selective inhibitor of phosphodiesterases, enzymes that degrade cAMP. Increased cAMP levels can enhance the transcription of nardilysin via PKA activation. | ||||||
8-Bromo-cAMP | 76939-46-3 | sc-201564 sc-201564A | 10 mg 50 mg | $126.00 $328.00 | 30 | |
8-Br-cAMP is a cell-permeable cAMP analog. It can activate PKA, potentially leading to increased transcription of nardilysin. | ||||||
SQ 22536 | 17318-31-9 | sc-201572 sc-201572A | 5 mg 25 mg | $95.00 $363.00 | 13 | |
SQ22536 is an adenylate cyclase inhibitor. It can decrease cAMP formation, leading to decreased PKA activity and potentially altering nardilysin expression. | ||||||
Vinpocetine | 42971-09-5 | sc-201204 sc-201204A sc-201204B | 20 mg 100 mg 15 g | $55.00 $214.00 $2400.00 | 4 | |
Vinpocetine is a PDE1 inhibitor, leading to increased cAMP levels, which can potentially enhance nardilysin expression via PKA activation. | ||||||
Zardaverine | 101975-10-4 | sc-201208 sc-201208A | 5 mg 25 mg | $88.00 $379.00 | 1 | |
Zardaverine inhibits PDE3 and PDE4, leading to increased cAMP levels. This can potentially enhance nardilysin expression via PKA activation. | ||||||
Papaverine | 58-74-2 | sc-279951 sc-279951A sc-279951B | 10 mg 50 mg 100 mg | $153.00 $265.00 $459.00 | ||
Papaverine inhibits various PDEs, leading to increased cAMP levels. This can potentially enhance nardilysin expression via PKA activation. | ||||||
Milrinone | 78415-72-2 | sc-201193 sc-201193A | 10 mg 50 mg | $165.00 $697.00 | 7 | |
Milrinone is a PDE3 inhibitor, leading to increased cAMP levels. This can potentially enhance nardilysin expression via PKA activation. | ||||||
Etazolate Hydrochloride | 35838-58-5 | sc-201186 sc-201186A | 5 mg 25 mg | $61.00 $255.00 | 5 | |
Etazolate is a PDE4 inhibitor, leading to increased cAMP levels. This can potentially enhance nardilysin expression via PKA activation. | ||||||